The multidisciplinary research team SyNaBi has taken a bioinspired approach to develop innovative biotechnologies for medical applications.
Nature is full of complex things that are elegant in their methods of fabrication. Inspiration from such elegant natural processes provides a path to develop new biotechnology systems to produce power and to create new medical diagnostic and therapeutic devices. The path is complex, but successful biomimicry of biological processes usually results in highly sensitive biotechnology devices. From its understanding of protein-lipid interactions, the SyNaBi team has pioneered the biotechnology for the production of power using biological membrane transport proteins incorporated in a biomimetic lipid bilayer membrane. The biomimetic lipid bilayer is an important bioinspired core component, which is self-assembled using principles derived from natural biology.
The research field of SyNaBi is based on combined skills of the team in
- Bioengineering of biomimetic membranes and biocompatible polymers,
- Biophysic and modeling,
- Molecular and cellular biology,
- Bioelectrochemistry, electrophysiology and biochemistry.
Implantable biofuel cells and biosensors:
We chose two biomimetic approaches to create bioinspired biofuel cells. The first was an enzymatic biofuel cell that generated electrical current from redox mechanisms. The second was a biomimetic biofuel cell that generated an electrical potential from ion transfer across a biomimetic membrane. The enzymatic biofuel cell, utilizing glucose and oxygen, is theorically able to work almost indefinitely as its substrates are always present in the body fluids. However, the biocompatibility and the long-term performance of this biofuel cell for a human implantation remains a real bottleneck. We are working on the design and the implantation of new enzymatic biofuel cells in different animal models. The implantation of such devices is challenging and a novel creative solution is to take a physiological point of view to address biocompatibility problems and electrical measurement techniques. We are now capable to implant these biofuel cells in large animals by analyzing the performance of the biofuel cells in real time.
We also initiate the biomimetic biofuel cell concept. It consists of a membrane transport protein (i.e ion channels) incorporated in a biomimetic membrane, which transforms a gradient of salt into a proton gradient. We also generate a 20 mV voltage with a 38 mm² flat membrane. This biomimetic membrane containing the NhaA sodium/ proton exchanger is stable for more than two weeks.
The use of immobilized enzymes or biomimetic membranes incorporating transport proteins allows us to create and open out a huge range of biosensors. The ceration of the biosensors also benefits from the miniaturization we are able to achieve through the application of nanotechnology, such as by the principles described here.
Other implantable devices:
We also focus on innovative medical devices capable of modifying the gut microbiota,involved in many pathologies (e.g morbid obesity, diabetes, chronic inflammatory diseases, Parkinson's disease). We are optimizing an intestinal reactor able to consume nutrients, modify the physicochemical conditions to which the microbiota is sensitive and produce molecules of interest. This reactor and a microbiota sampler are yet tested in vivo. Those two projects are supported by the SATT Linksium (Technology transfert & startup building).
Systems for personalised medicine and HTS :
We develop these systems by relying on the concepts of “biomimetics”. This concept was first introduced by Otto Schmidt in 1969 during a presentation at the 3rd International Biophysics Congress in Boston. Such a biomimetic approach, also used in the field of nanobiotechnologies, means that the fabrication processes for the systems are based on the way that natural systems a “self-assembled”. An example is our involvement in the UroLOC project, which is an ambitious scheme in collaboration with scientists from the CEA and CNRS to develop a nanostructured 3D polyelectrolyte scaffold that is connected to a microfluidic biochip to examine the influence of the microenvironment on cancerous cells from the prostate and to identify new biomarkers for prostate cancer.
This basic research has already given rise to 2 patents and 3 publications, one in the journal Biomaterials, where we show that a positively-charged polyelectrolyte film of only several nanometres in thickness reduced the clustering and proliferation of cancerous prostate cells.
Our ongoing work is developing those fundamental results into a diagnostic device for personalized medicine and high-throughput-screening (HTS).
- ANR - projet BIOWATTS
- ANR - projet IMABIC
- SATT - projet BIOPILE
- SATT - projet MICROBIOTE SAMPLER
- SATT - projet MODULATEUR MICROBIOTE
- Ligue Contre le Cancer - projet VE-Cadherin / phospholipids
- ValoGRAL - projet UroLOC
- Investissement d’Avenir - projet IBFC
- ANR - projet BROCOLI
- ANR - projet M-GBFC
- Horizon 2020 - projet UroLOC (complementary list)
- AGIR-UGA - projet MEKANO
Projet pré-maturation start-up BIOPILE
Projet TAENIA artificiel
- Donald MARTIN (Enseignant chercheur)
- Jean-Pierre Alcaraz (IT-BIATSS)
- Céline Beaujean (IT-BIATSS)
- Marco Maccarini (Chercheur)
- Donald Martin (Enseignant chercheur)
- Abdelkader Zebda (Chercheur)
- Awatef Ben-tahar (IT-BIATSS)
- Véronica Casali (IT-BIATSS)
- Izabela Kondratowicz (Chercheur contractuel)
- Marco Mauri (Post-doc)
- Antoine Paccard (IT-BIATSS)
- Rémi Soutrenon (IT-BIATSS)
- Valéria Italia (Doctorant)
Anciens membres de l'equipe
- Barry Stidder (Postdoc)
- Lavinia Liguori (Postdoc)
- Landry Gayet (Postdoc)
- Sarra El Ichi (Postdoc)
- Geraldine Penven (PhD)
- Thomas Soranzo (Postdoc)
University of East Anglia, Norwich Medical School (U.K.). MESA+ Institute for Nanotechnology. University of Twente (The Netherlands). Tyndall National Institute (Ireland), University of Turku (Finland). University of Melbourne (Australia)
- France : Synthelis SAS, Sorin Group, Biopic SAS. ST Microelectronics, Groupe Absiskey - Vitamib,
- International : Creamedix GmbH (Allemagne), Mosaiques Diagnostics GmbH (Allemagne),0stendum R&D b.v. (Pays-BAS), Seagull Technologies Pty Ltd (Australie), SDX Tethered Membrancs Pty Ltd (Australie)
is teaching in BIO4111 for Master1 in Biology "experimental approch in biology".
- responsible of UE MCMB7U00 "Outils Moléculaires en Santé" de M1 Ingénierie pour la Santé /Science et Management des Biotechnologies (SMB)
- responsible of UE MCXA0008 UE "Micro and Nanotechnologies for Health" de Master 2 ISM
- is teaching in UE ‟Biosensors and high throughput analysisˮ - 5PMBBTA7 Grenoble INP Phelma
- Mathematic in PACES (Grenoble)
- Biostatistics in PACES (Grenoble)
- GMCAO Master Informatique Bio Médicale (Paris)